Novel Doxorubicin Derivatives: Synthesis and Cytotoxicity Study in 2D and 3D in Vitro Models

Roman Akasov ^1,2 * , Maria Drozdova ^1,3, Daria Zaytseva-Zotova ¹, Maria Leko ⁴, Pavel Chelushkin ⁴, Annie Marc ⁵, Isabelle Chevalot ⁵, Sergey Burov ⁴, Natalia Klyachko ⁶, Thierry Vandamme ⁷, Elena Markvicheva ¹

Cited by CrossRef: 14

1- Trushina D, Akasov R, Khovankina A, Borodina T, Bukreeva T, Markvicheva E. Doxorubicin-loaded biodegradable capsules: Temperature induced shrinking and study of cytotoxicity in vitro. Journal of Molecular Liquids. 2019;284:215 [Crossref]

2- Capelôa T, Benyahia Z, Zampieri L, Blackman M, Sonveaux P. Metabolic and non-metabolic pathways that control cancer resistance to anthracyclines. Seminars in Cell & Developmental Biology. 2020;98:181 [Crossref]

3- Zhukova O. Polymer Derivatives of Anticancer Drugs: Features of Synthesis and Biological Activity. Ref J Chem. 2019;9(1):1 [Crossref]

4- Harris M, Hawkins C, Miles M. Tetrazolium reduction assays under-report cell death provoked by clinically relevant concentrations of proteasome inhibitors. Mol Biol Rep. 2020;47(6):4849 [Crossref]

5- Vatankhah Z, Dehghani E, Salami-Kalajahi M, Roghani-Mamaqani H. One-step fabrication of low cytotoxic anisotropic poly(2-hydroxyethyl methacrylate-co-methacrylic acid) particles for efficient release of DOX. Journal of Drug Delivery Science and Technology. 2019;54:101332 [Crossref]

6- Cakan-Akdogan G, Ersoz E, Sozer S, Gelinci E. An in vivo zebrafish model reveals circulating tumor cell targeting capacity of serum albumin nanoparticles. Journal of Drug Delivery Science and Technology. 2022;75:103658 [Crossref]

7- Willers C, Svitina H, Rossouw M, Swanepoel R, Hamman J, Gouws C. Models used to screen for the treatment of multidrug resistant cancer facilitated by transporter-based efflux. J Cancer Res Clin Oncol. 2019;145(8):1949 [Crossref]

8- He Y, de Araújo Júnior R, Cavalcante R, Yu Z, Schomann T, Gu Z, Eich C, Cruz L. Effective breast cancer therapy based on palmitic acid-loaded PLGA nanoparticles. Biomaterials Advances. 2023;145:213270 [Crossref]

9- Čiužas D, Krugly E, Petrikaitė V. The fabrication method impacts biological properties of microfibrous three-dimensional in vitro cell culture scaffolds and their applications in drug screening. Materials Today Communications. 2024;39:108707 [Crossref]

10- Federico S, Martorana A, Pitarresi G, Palumbo F, Fiorica C, Giammona G. Development of stimulus-sensitive electrospun membranes based on novel biodegradable segmented polyurethane as triggered delivery system for doxorubicin. Biomaterials Advances. 2022;136:212769 [Crossref]

11- Paukovcekova S, Krchniakova M, Chlapek P, Neradil J, Skoda J, Veselska R. Thiosemicarbazones Can Act Synergistically with Anthracyclines to Downregulate CHEK1 Expression and Induce DNA Damage in Cell Lines Derived from Pediatric Solid Tumors. IJMS. 2022;23(15):8549 [Crossref]

12- Bissoli I, Muscari C. Doxorubicin and α-Mangostin oppositely affect luminal breast cancer cell stemness evaluated by a new retinaldehyde-dependent ALDH assay in MCF-7 tumor spheroids. Biomedicine & Pharmacotherapy. 2020;124:109927 [Crossref]

13- Swedan H, Kassab A, Gedawy E, Elmeligie S. Topoisomerase II inhibitors design: Early studies and new perspectives. Bioorganic Chemistry. 2023;136:106548 [Crossref]

14- Sadeghi F, Afkhami A, Madrakian T, Ghavami R. A new approach for simultaneous calculation of pIC50 and logP through QSAR/QSPR modeling on anthracycline derivatives: a comparable study. J IRAN CHEM SOC. 2021;18(10):2785 [Crossref]

15- Sadeghi F, Afkhami A, Madrakian T, Ghavami R. Computational study to select the capable anthracycline derivatives through an overview of drug structure-specificity and cancer cell line-specificity. Chem Pap. 2021;75(2):523 [Crossref]